StockData

KALA BIO, Inc. (KALA) company profile

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$3.43−0.40 (-10.44%)

Close on Nov 17, 2026Market cap $66.34MP/E –Yield –

About Kala Bio

Pharmaceutical Preparations, SIC 2834

KALA BIO, Inc. is a transitioning biopharmaceutical company that focuses on developing an on-premises artificial intelligence infrastructure platform tailored for the biotechnology and pharmaceutical sectors. Operating through its licensed Researgency platform, the company intends to provide platform-as-a-service offerings, implementation support, data analytics, and maintenance subscriptions. These tools allow biotechnology firms, pharmaceutical enterprises, and contract research organizations to analyze biological datasets, coordinate research workflows, and preserve data sovereignty within private environments. Concurrently, the company seeks to monetize its proprietary mesenchymal stem cell secretome biologics portfolio through licensing, sales, or partnerships following the discontinuation of its clinical-stage candidate KPI-012.

Historically, the enterprise conducted preclinical evaluations and clinical trials across 45 sites in the United States, alongside additional operations initiated in Mexico and Argentina. The provided filing text does not report current employee headcount, facility figures, or active corporate headquarters locations.

Summary of the business section of Kala Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
KALA BIO, Inc.
Founded
2009
Headquarters
Arlington, MA
Address
1167 Massachusetts Avenue 02476
Phone
(781) 996-5252
Employees
6, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
HTL International, LLC, Houston, Texas

Stock & identifiers

Ticker
KALA
Exchange
Nasdaq
IPO date
Jul 20, 2017
Shares outstanding
19M, Aug 14, 2026
Public float
$24.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-50 reverse, May 11, 2026; 1-for-50 reverse, Oct 21, 2022
SEC CIK
1479419
CUSIP
483119301
ISIN
US4831193010
FIGI
BBG001J2MVT8
Share class FIGI
BBG001V0GBM6
LEI
529900Y7RO0C9P0TX474
EIN
27-0604595

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Avraham MinkowitzChief Executive Officer, Director–
David E. LazarChief Executive Officer, Director0
Romulus K. BrazzellSEE REMARKS35,952
Mary ReumuthCHIEF FINANCIAL OFFICER28,906
Darius KharabiCHIEF BUSINESS OFFICER41,760
Brendan P. PurdyDirector–
Yonatan C. ColmanDirector–
Chaim D. BergerDirector–
Hillel D. PosenDirector–
Todd BazemoreDirector35,933
Mark T. IwickiDirector103,540
Andrew I. KovenDirector16,972
Howard B. RosenDirector16,502
Gregory D. PerryDirector13,344
C. Daniel MyersDirector10,374
Marjan FaridDirector10,242

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$906.64K-$1.01M$2.42M$1–
FY2024$1.49M$1.26M$935.12K$7–
FY2023$8.34M$3.75M$2.93M$2–
FY2022$1.87M$1.22M$1.01M$11–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Mark Iwicki
Former Chief Executive Officer
$111.87K–$166.41K$627.47K$896$906.64K-39%
Todd Bazemore
Former Interim Chief Executive Officer, President and Chief Operating Officer
$489.11K$585.45K$76.05K$2.26M$64.15K$3.48M+266%
Kim Brazzell
Former Head of Research and Development and Chief Medical Officer
$420.00K$522.00K$76.05K$285.04K$55.08K$1.36M+48%
Mary Reumuth
Former Chief Financial Officer
$438.96K$475.55K$76.05K$285.04K$47.00K$1.32M+70%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 20, 2017
Offer price
$15.00
Securities offered
6,000,000
Gross proceeds
$90.00M
Exchange
Nasdaq
First trading day
Jul 20, 2017
First-day close
$18.49+23.3%
Lock-up ends (est.)
Jan 16, 2018

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025 and March 31, 2026, we had a total of 6 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?